Bronte Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.2M Buy
202,057
+3,623
+2% +$254K 1.23% 20
2026
Q2
$13.9M Buy
198,434
+178
+0.1% +$13K 1.49% 17
2026
Q1
$14.3M Buy
+198,256
New +$11.3M 1.41% 16

Other funds holding NKTR

Bronte Capital Management's NKTR Position: Q3 2026 in Review

Bronte Capital Management increased its Nektar Therapeutics (NKTR) stake by 1.8% in Q3 2026, buying an estimated $254K and bringing the position to 202,057 shares worth $12.2M. The position accounts for 1.23% of the portfolio, ranked #20.

Bronte Capital Management first reported a position in NKTR in Q1 2026 and has held it in 3 quarters since. The position peaked at $14.3M in Q1 2026. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Bronte Capital Management held 202,057 shares of Nektar Therapeutics worth $12.2M as of Q3 2026.
  • Bronte Capital Management bought 3,623 Nektar Therapeutics shares in Q3 2026, an estimated $254K.
  • Nektar Therapeutics made up 1.23% of Bronte Capital Management's portfolio in Q3 2026, its #20 holding.
  • Bronte Capital Management first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Bronte Capital Management's Nektar Therapeutics position peaked at $14.3M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Bronte Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.